Assessment of Corneal Graft Attachment in Patients With Fuchs Endothelial Corneal Dystrophy Following DMEK Using Ultra-high Resolution OCT
Primary Purpose
Fuchs' Endothelial Dystrophy
Status
Completed
Phase
Not Applicable
Locations
Austria
Study Type
Interventional
Intervention
Ultrahigh resolution Spectral Domain OCT
Sponsored by
About this trial
This is an interventional diagnostic trial for Fuchs' Endothelial Dystrophy focused on measuring Fuchs' Endothelial Dystrophy, DMEK
Eligibility Criteria
Inclusion Criteria:
- Men and women aged over 18 years scheduled for primary DMEK because of Fuchs' Endothelial Dystrophy
Exclusion Criteria:
- Any disease inhibiting OCT acquisition; such as blepharospasm, severe tremor or immobility
- Any previous intraocular surgery other than cataract extraction
- Previous clinically significant ocular trauma in the study eye, as judged by the investigator
- Pregnancy, planed pregnancy, or lactating
- Appointment of a custodian
- Progressive retinal disease
- History or presence of glaucoma
Sites / Locations
- Medical University Vienna, Department of Clinical Pharmacology
- Vienna Institute for Research in Ocular Surgery (VIROS)
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Patients with Fuchs endothelial dystrophy scheduled for DMEK
Arm Description
Outcomes
Primary Outcome Measures
Change in best corrected visual acuity at 12 months compared to baseline using a standardized protocol with the Early Treatment Diabetic Retinopathy (ETDRS) charts (4 meters).
Visual acuity will be measured using a standardized protocol with the Early Treatment Diabetic Retinopathy (ETDRS) charts (4 meters).
Area of attached graft after DMEK
Secondary Outcome Measures
Number of patients in which rebubbling has to be performed
Number of patients needing retreatment
Best corrected visual acuity at 6 months using a standardized protocol with the Early Treatment Diabetic Retinopathy (ETDRS) charts (4 meters).
Visual acuity will be measured using a standardized protocol with the Early Treatment Diabetic Retinopathy (ETDRS) charts (4 meters).
Central corneal thickness
Corneal endothelial cell count
Demographic risk factors such as age
Demographic risk factors such as gender
Demographic risk factors, such as family history
Demographic risk factors, such as smoking status
Full Information
NCT ID
NCT02542644
First Posted
August 31, 2015
Last Updated
April 6, 2022
Sponsor
Medical University of Vienna
1. Study Identification
Unique Protocol Identification Number
NCT02542644
Brief Title
Assessment of Corneal Graft Attachment in Patients With Fuchs Endothelial Corneal Dystrophy Following DMEK Using Ultra-high Resolution OCT
Official Title
Assessment of Corneal Graft Attachment in Patients With Fuchs Endothelial Corneal Dystrophy Following Descemet's Membrane Endothelial Keratoplasty Using Ultra-high Resolution Optical Coherence Tomography
Study Type
Interventional
2. Study Status
Record Verification Date
April 2022
Overall Recruitment Status
Completed
Study Start Date
November 15, 2017 (Actual)
Primary Completion Date
March 15, 2022 (Actual)
Study Completion Date
March 15, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Medical University of Vienna
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Fuchs endothelial corneal dystrophy (FECD) is a progressive disease characterized by the loss of endothelial cells, thickening of Descemet's membrane and deposition of extracellular matrix in the form of guttae. This result in failure of the endothelium to support corneal deturgescence leading to corneal edema. Affected patients complain about blurred vision at early stages of the disease which can progress to blindness. The pathophysiology of the disease is still unclear, but several studies point towards a genetic susceptibility. Additional risk factors that have been identified are female sex, smoking and older age.
While for a long time penetrating keratoplasty (PKP) was the only therapy available for affected patients, in the recent years less invasive methods such as descemet's membrane endothelial keratoplasty (DMEK) have been developed. In DMEK, only the Descemet's membrane and the endothelium is removed and replaced with the corresponding parts from a donor's cornea. For FECD, this brings the advantage that only the diseased part of the cornea is replaced. Graft detachment has been identified as the main complication following DMEK.
In the investigators' study, an ultra high resolution OCT system will be used to detect graft detachment in patients with FECD after DMEK. With this technique, even small detachments can be visualized. The area of graft detachment will be evaluated at predefined time points after surgery and correlated to visual acuity. A follow-up of one year will be performed in order to investigate the predictive value of graft adherence status at several time points for visual outcome.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fuchs' Endothelial Dystrophy
Keywords
Fuchs' Endothelial Dystrophy, DMEK
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
12 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Patients with Fuchs endothelial dystrophy scheduled for DMEK
Arm Type
Other
Intervention Type
Device
Intervention Name(s)
Ultrahigh resolution Spectral Domain OCT
Intervention Description
The area of graft detachment will be measured by a customized ultra high-resolution OCT for the cornea.
A spectrometer based ultrahigh resolution Spectral Domain OCT (SDOCT) system operating at 800 nm for the anterior chamber will be employed in the present study. The spectrum of the Ti:Sapphire laser light source is centered at 800 nm. With a full width at half maximum bandwidth of 170 nm, the axial resolution is 1.3 μm in the cornea. The transverse resolution of the employed OCT system is 21 μm at the front surface of the cornea. For measurement, patients will place their head in a modified slit lamp head rest. During the measurement period, patients will be asked to look straight forward onto an internal fixation target and to avoid blinking. Different scattering patterns, e.g. raster, circular and spiral scans will be employed.
Primary Outcome Measure Information:
Title
Change in best corrected visual acuity at 12 months compared to baseline using a standardized protocol with the Early Treatment Diabetic Retinopathy (ETDRS) charts (4 meters).
Description
Visual acuity will be measured using a standardized protocol with the Early Treatment Diabetic Retinopathy (ETDRS) charts (4 meters).
Time Frame
1-2 days, 1 week, 1 month, 6 months and 12 months after DMEK
Title
Area of attached graft after DMEK
Time Frame
12 months after DMEK
Secondary Outcome Measure Information:
Title
Number of patients in which rebubbling has to be performed
Time Frame
12 months
Title
Number of patients needing retreatment
Time Frame
12 months
Title
Best corrected visual acuity at 6 months using a standardized protocol with the Early Treatment Diabetic Retinopathy (ETDRS) charts (4 meters).
Description
Visual acuity will be measured using a standardized protocol with the Early Treatment Diabetic Retinopathy (ETDRS) charts (4 meters).
Time Frame
6 months
Title
Central corneal thickness
Time Frame
12 months
Title
Corneal endothelial cell count
Time Frame
12 months
Title
Demographic risk factors such as age
Time Frame
12 months
Title
Demographic risk factors such as gender
Time Frame
12 months
Title
Demographic risk factors, such as family history
Time Frame
12 months
Title
Demographic risk factors, such as smoking status
Time Frame
12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
98 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Men and women aged over 18 years scheduled for primary DMEK because of Fuchs' Endothelial Dystrophy
Exclusion Criteria:
Any disease inhibiting OCT acquisition; such as blepharospasm, severe tremor or immobility
Any previous intraocular surgery other than cataract extraction
Previous clinically significant ocular trauma in the study eye, as judged by the investigator
Pregnancy, planed pregnancy, or lactating
Appointment of a custodian
Progressive retinal disease
History or presence of glaucoma
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Katarzyna Witkowska, MD
Organizational Affiliation
Department of Clinical Pharmacology, Medical University of Vienna
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medical University Vienna, Department of Clinical Pharmacology
City
Vienna
ZIP/Postal Code
1090
Country
Austria
Facility Name
Vienna Institute for Research in Ocular Surgery (VIROS)
City
Vienna
ZIP/Postal Code
1140
Country
Austria
12. IPD Sharing Statement
Learn more about this trial
Assessment of Corneal Graft Attachment in Patients With Fuchs Endothelial Corneal Dystrophy Following DMEK Using Ultra-high Resolution OCT
We'll reach out to this number within 24 hrs